SCHEMBL16436403

SCHEMBL16436403

C=C(C)C(=O)Oc1ccc(C#Cc2ccc(-c3ccc(-c4ccc(OC(=O)C(=C)C)cc4)o3)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.46
KMT2A Q03164 2/20 0.43
ATM Q13315 1/20 0.43
NQO2 P16083 7/20 0.40
MAPT P10636 4/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
PKM P14618 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TP53 P04637 3/20 0.36
THRB P10828 2/20 0.36
ERCC5 P28715 1/20 0.35
FEN1 P39748 1/20 0.35
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16436313 0.92 ELANE (0.40) ELANEKMT2AATMNQO2MAPT
SCHEMBL16436217 0.92 ELANE (0.42) ELANEKMT2AATMNQO2MAPT
SCHEMBL16436196 0.91 ELANE (0.53) ELANEKMT2AATMNQO2MAPT
SCHEMBL16436415 0.91 ELANE (0.41) ELANEKMT2AATMNQO2MAPT
SCHEMBL16436282 0.90 ELANE (0.51) ELANEKMT2AATMNQO2MAPT
SCHEMBL16182693 0.86 ELANE (0.57) ELANEKMT2AATMMAPTKDM4E
SCHEMBL16182736 0.86 ELANE (0.57) ELANEKMT2AATMMAPTKDM4E
SCHEMBL7766154 0.86 ELANE (0.57) ELANEKMT2AATMMAPTKDM4E
SCHEMBL16436332 0.86 ELANE (0.37) ELANEKMT2AATMNQO2MAPT
SCHEMBL16436221 0.86 ELANE (0.37) ELANEKMT2AATMNQO2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9315603-B2 Polymerizable compound having oxygen-containing five-membered ring, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2016-04-19 US disclosed
US-9315603-B2 Polymerizable compound having oxygen-containing five-membered ring, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2016-04-19 US disclosed
US-20150034871-A1 POLYMERIZABLE COMPOUND HAVING OXYGEN-CONTAINING FIVE-MEMBERED RING, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC PETROCHEMICAL CORPORATION (JP) 2015-02-05 US disclosed
US-20150034871-A1 POLYMERIZABLE COMPOUND HAVING OXYGEN-CONTAINING FIVE-MEMBERED RING, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC PETROCHEMICAL CORPORATION (JP) 2015-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150034871-A1 POLYMERIZABLE COMPOUND HAVING OXYGEN-CONTAINING FIVE-MEMBERED RING, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE OCIAD1, OCIAD2, SCO2 ELANE 2946/4885KMT2A 3863/4885ATM 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.